0001140361-23-023233 | 10-Q | XBRL Viewer | Rocket Pharmaceuticals INC

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2023	May 01, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Document Transition Report	false
Entity File Number	001-36829
Entity Registrant Name	Rocket Pharmaceuticals, Inc.
Entity Central Index Key	0001281895
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3475813
Entity Address, Address Line One	9 Cedarbrook Drive
Entity Address, City or Town	Cranbury
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08512
City Area Code	609
Local Phone Number	659-8001
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	RCKT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		80,461,335

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 64,579	$ 140,517
Investments	266,505	215,877
Prepaid expenses and other current assets	6,949	7,666
Total current assets	338,033	364,060
Property and equipment, net	30,588	29,009
Goodwill	39,154	39,154
Intangible assets	25,724	25,724
Restricted cash	1,340	1,340
Deposits	459	608
Investments	28,957	43,276
Operating lease right-of-use assets	4,369	1,972
Finance lease right-of-use asset	46,133	46,664
Total assets	514,757	551,807
Current liabilities:
Accounts payable and accrued expenses	28,609	36,660
Operating lease liabilities, current	849	773
Finance lease liability, current	1,748	1,736
Total current liabilities	31,206	39,169
Operating lease liabilities, non-current	3,506	1,088
Finance lease liability, non-current	19,294	19,269
Other liabilities	1,875	2,595
Total liabilities	55,881	62,121
Commitments and contingencies (Note 12)
Stockholders' equity:
Common stock, $0.01 par value, 120,000,000 shares authorized; 80,412,194 and 79,123,312 shares issued and 80,409,623 and 79,120,741 shares outstanding at March 31, 2023 and December 31, 2022, respectively	804	791
Treasury stock, at cost, 2,571 common shares at March 31, 2023 and December 31, 2022, respectively	(47)	(47)
Additional paid-in capital	1,230,319	1,203,074
Accumulated other comprehensive loss	(90)	(357)
Accumulated deficit	(772,110)	(713,775)
Total stockholders' equity	458,876	489,686
Total liabilities and stockholders' equity	514,757	551,807
Series A Convertible Preferred Shares [Member]
Stockholders' equity:
Preferred stock	0	0
Series B Convertible Preferred Shares [Member]
Stockholders' equity:
Preferred stock	$ 0	$ 0

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	80,412,194	79,123,312
Common stock, shares outstanding (in shares)	80,409,623	79,120,741
Treasury stock, at cost (in shares)	2,571	2,571
Series A Convertible Preferred Shares [Member]
Stockholders' equity:
Preferred stock, shares authorized (in shares)	300,000	300,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series B Convertible Preferred Shares [Member]
Stockholders' equity:
Preferred stock, shares authorized (in shares)	300,000	300,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Consolidated Statements of Operations [Abstract]
Revenue	$ 0	$ 0
Operating expenses:
Research and development	46,371	30,794
General and administrative	15,823	11,770
Total operating expenses	62,194	42,564
Loss from operations	(62,194)	(42,564)
Interest expense	(468)	(464)
Interest and other income, net	1,908	623
Accretion of discount and amortization of premium on investments, net	2,419	(577)
Net loss	$ (58,335)	$ (42,982)
Net loss per share - basic (in dollars per share)	$ (0.73)	$ (0.67)
Net loss per share - diluted (in dollars per share)	$ (0.73)	$ (0.67)
Weighted-average common shares outstanding - basic (in shares)	79,453,519	64,509,721
Weighted-average common shares outstanding - diluted (in shares)	79,453,519	64,509,721

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Consolidated Statements of Comprehensive Loss [Abstract]
Net loss	$ (58,335)	$ (42,982)
Other comprehensive loss
Net unrealized gain (loss) on investments	272	(468)
Total comprehensive loss	$ (58,063)	$ (43,450)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Treasury Stock, Common [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income/(Loss) [Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Dec. 31, 2021	$ 645	$ 0	$ 946,152	$ (161)	$ (491,912)	$ 454,724
Beginning Balance (in shares) at Dec. 31, 2021	64,505,889
Issuance of common stock pursuant to exercise of stock options	$ 0	0	76	0	0	76
Issuance of common stock pursuant to exercise of stock options (in shares)	16,168
Unrealized comprehensive gain (loss) on investments	$ 0	0	0	(468)	0	(468)
Stock-based compensation	0	0	6,270	0	0	6,270
Net loss	0	0	0	0	(42,982)	(42,982)
Ending Balance at Mar. 31, 2022	$ 645	0	952,498	(629)	(534,894)	417,620
Ending Balance (in shares) at Mar. 31, 2022	64,522,057
Beginning Balance at Dec. 31, 2022	$ 791	(47)	1,203,074	(357)	(713,775)	489,686
Beginning Balance (in shares) at Dec. 31, 2022	79,123,312
Issuance of common stock pursuant to exercise of stock options	$ 1	0	1,113	0	0	1,114
Issuance of common stock pursuant to exercise of stock options (in shares)	88,429
Issuance of common stock pursuant to vesting of restricted stock units	$ 1	0	(1)	0	0	0
Issuance of common stock pursuant to vesting of restricted stock units (in shares)	126,060
Issuance of common stock pursuant to exercise of warrants	$ 1	0	6	0	0	7
Issuance of common stock pursuant to exercise of warrant (in shares)	126,093
Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs	$ 10	0	17,212	0	0	17,222
Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs (in shares)	948,300
Unrealized comprehensive gain (loss) on investments	$ 0	0	0	267	0	267
Stock-based compensation	0	0	8,915	0	0	8,915
Net loss	0	0	0	0	(58,335)	(58,335)
Ending Balance at Mar. 31, 2023	$ 804	$ (47)	$ 1,230,319	$ (90)	$ (772,110)	$ 458,876
Ending Balance (in shares) at Mar. 31, 2023	80,412,194

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating Activities:
Net loss	$ (58,335)	$ (42,982)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property and equipment	1,135	767
Amortization of finance lease right of use asset	538	535
Write down of property and equipment, net	0	40
Stock-based compensation	8,915	6,270
Amortization of premium and accretion of discount on investments, net	(2,343)	577
Changes in operating assets and liabilities:
Prepaid expenses and other assets	866	(3,936)
Accounts payable and accrued expenses	(7,750)	(491)
Operating lease liabilities	97	(33)
Finance lease liability	37	45
Other liabilities	(720)	(15)
Net cash used in operating activities	(57,560)	(39,223)
Investing activities:
Purchases of investments	(96,034)	(143,023)
Proceeds from maturities of investments	62,335	81,983
Payments made to acquire right of use asset	(7)	0
Purchases of property and equipment	(3,015)	(1,955)
Net cash used in investing activities	(36,721)	(62,995)
Financing activities:
Issuance of common stock, pursuant to exercise of stock options	1,114	76
Exercise of warrants	7	0
Issuance of common stock pursuant to the at-the-market offering program, net of issuance costs	17,222	0
Net cash provided by financing activities	18,343	76
Net change in cash, cash equivalents and restricted cash	(75,938)	(102,142)
Cash, cash equivalents and restricted cash at beginning of period	141,857	234,037
Cash, cash equivalents and restricted cash at end of period	65,919	131,895
Supplemental disclosure of non-cash financing and investing activities:
Accrued purchases of property and equipment, ending balance	1,794	1,635
Unrealized gain (loss) on investments	$ 267	$ (468)

Nature of Business

3 Months Ended

Mar. 31, 2023

Nature of Business [Abstract]

Nature of Business

1.	Nature of Business

Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) is a clinical-stage, multi-platform biotechnology company focused on the development of first, only and best in-class gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases. The Company has three clinical-stage ex vivo lentiviral vector (“LV”) programs. These include programs for Fanconi Anemia (“FA”), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I (“LAD-I”), a genetic disorder that causes the immune system to malfunction and Pyruvate Kinase Deficiency (“PKD”), a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. Of these, both the Phase 2 FA program and the Phase 1/2 LAD-I program produced data read outs in 2022 and regulatory filings in the United States (“U.S.”) and Europe (“EU”) are anticipated in 2023. Additional work on a gene therapy program for the less common FA subtypes C and G is ongoing. In the U.S., the Company also has a clinical stage in vivo adeno-associated virus (“AAV”) program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. The Danon program is currently in an ongoing Phase 1 trial and pivotal Phase 2 study initiation expected in the second quarter of 2023. Additionally, the Company has an AAV vector program targeting Plakophilin-2 Arrhythmogenic Cardiomyopathy (“PKP2-ACM”), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death. This program, also referred to as Pegasus, will be approaching IND submission in the second quarter of 2023. As a result of the Company’s acquisition of Renovacor Inc. (“Renovacor”) (see Note 14 “Renovacor Acquisition”), the Company is able to utilize recombinant AAV9-based gene therapy designed to slow or halt progression of BAG3 Dilated Cardiomyopathy (“DCM”), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood. The Company has global commercialization and development rights to all of these product candidates under royalty-bearing license agreements.

Risks and Liquidity

3 Months Ended

Mar. 31, 2023

Risks and Liquidity [Abstract]

Risks and Liquidity

2.	Risks and Liquidity

The Company has not generated any revenue and has incurred losses since inception. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of drug candidate development, technological uncertainty, uncertainty regarding patents and proprietary rights, having no commercial manufacturing experience, marketing or sales capability or experience, dependency on key personnel, compliance with government regulations and the need to obtain additional financing. Drug candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities.

The Company’s product candidates are in the development and clinical stage. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies.

The Company’s consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. The Company has experienced negative cash flows from operations and had an accumulated deficit of $772.1 million as of March 31, 2023. As of March 31, 2023, the Company had $360.0 million of cash, cash equivalents and short-term and long-term investments. The Company expects such resources will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the first half of 2025.

On February 28, 2022, the Company entered into a sales agreement (the “Sales Agreement”), with Cowen and Company, LLC (“Cowen”), with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share, having an aggregate offering price of up to $200 million (the “Shares”) through Cowen as its sales agent. Through March 31, 2023, the Company has sold 4.2 million shares of common stock for net proceeds of $63.8 million pursuant to the at-the-market offering program (see Note 8 “Stockholders’ Equity”), including 0.9 million shares for net proceeds of $17.2 million during the three months ended March 31, 2023.

In the longer term, the future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company’s failure to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2023

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies [Abstract]

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies

3.	Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited interim consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the year ended December 31, 2022 included in the Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2023 (“2022 Form 10-K”). The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s consolidated financial position as of March 31, 2023 and the results of its operations and its cash flows for the three months ended March 31, 2023. The financial data and other information disclosed in these consolidated notes related to the three months ended March 31, 2023 and 2022 are unaudited. The results for the three months ended March 31, 2023 are not necessarily indicative of results to be expected for the year ending December 31, 2023 and any other interim periods or any future year or period.

Significant Accounting Policies

The significant accounting policies used in the preparation of these consolidated financial statements for the three months ended March 31, 2023 are consistent with those disclosed in Note 3 to the consolidated financial statements in the 2022 Form 10-K with most significant policies also being listed here.

Principles of Consolidation

The consolidated financial statements represent the consolidation of the accounts of the Company and its subsidiaries in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany accounts have been eliminated in consolidation.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to goodwill and intangible asset impairments, the accrual of research and development (“R&D”) expenses, the valuation of equity transactions and stock-based awards. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.

Cash, Cash Equivalents and Restricted Cash

Cash, cash equivalents and restricted cash consists of bank deposits, certificates of deposit and money market accounts with financial institutions. Cash equivalents are carried at cost which approximates fair value due to their short-term nature and which the Company believes do not have a material exposure to credit risk. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Company’s cash and cash equivalent accounts, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.

Restricted cash consists of deposits collateralizing letters of credit issued by a bank in connection with the Company’s operating leases (see Note 12 “Commitments and Contingencies” for additional disclosures) and a deposit collateralizing a letter of credit issued by a bank supporting the Company’s corporate credit card. Cash, cash equivalents and restricted cash consist of the following:

	March 31,		December 31,
	2023		2022
Cash and cash equivalents	$	64,579	$	140,517
Restricted cash		1,340		1,340
	$	65,919	$	141,857

Concentrations of credit risk and off-balance sheet risk

Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and available-for-sale securities. The Company maintains its cash and cash equivalent balances with high-quality financial institutions and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company’s marketable securities consist of U.S. Treasury Securities, Commercial Paper and Corporate and Agency Bonds. The Company’s investment policy limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure.

Investments

Investments consist of investments in U.S. Treasury Securities, Commercial Paper and Corporate and Agency Bonds. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. The Company classifies its investments as available-for-sale pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standard Codification (“ASC”) 320, Investments—Debt and Equity Securities. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive income (loss) in stockholders’ equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. Realized gains and losses are included in investment income on a specific-identification basis. For the three months ended March 31, 2023, there were net unrealized gains on investments of $0.3 million. For the three months ended March 31, 2022, there were net unrealized losses on investments of $0.5 million.

Intangible Assets

Intangible assets related to in process research and development (“IPR&D”) projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. IPR&D intangible assets which are determined to have had a drop in their fair value are adjusted downward and an expense is recognized in R&D expenses in the Consolidated Statements of Operations. These IPR&D intangible assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment based on indicators including progress of R&D activities, changes in projected development of assets, and changes in regulatory environment and future commercial markets.

Fair Value Measurements

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. FASB ASC 820, Fair Value Measurements and Disclosures, establishes a hierarchy of inputs used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:

•

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

•

Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

•

Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The fair value of the Company’s financial instruments, including cash and cash equivalents, restricted cash, deposits, accounts payable and accrued expenses approximate their respective carrying values due to the short-term nature of most of these instruments.

Warrants

The Company accounts for stock warrants as either equity instruments, liabilities or derivative liabilities in accordance with ASC Topic 480, Distinguishing Liabilities from Equity (”ASC 480”) and/or ASC Topic 815, Derivatives and Hedging (”ASC 815”), depending on the specific terms of the warrant agreement. Liability-classified warrants are recorded at their estimated fair values at each reporting period until they are exercised, terminated, reclassified or otherwise settled. Changes in the estimated fair value of liability-classified warrants are included in interest and other income in the Company’s consolidated statement of operations.

Stock-Based Compensation

The Company measures the compensation expense of employee and non-employee services received in exchange for an award of equity instruments based on the fair value of the award on the grant date. That cost is recognized over the requisite service period of the awards on a straight-line basis with forfeitures recognized as they occur.

The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient’s payroll costs and services are classified or in which the award recipient’s service payments are classified.

Income Taxes

In May 2022, the Company received a notice from the New York City Department of Finance regarding an audit of the NYC Biotechnology Credit for the tax periods ended December 31, 2018 through December 31, 2020, which is ongoing as of March 31, 2023.

Recent Accounting Pronouncements

There were no recent accounting pronouncements that impacted the Company, or which had a significant effect on the consolidated financial statements.

Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2023

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments

4.	Fair Value of Financial Instruments

Items measured at fair value on a recurring basis are the Company’s investments. The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy:

	Fair Value Measurements as of
	March 31, 2023 Using:
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market mutual funds	$	31,353	$	-	$	-	$	31,353
Corporate Bonds		-		3,778		-		3,778
United States Treasury securities		7,670		-		-		7,670
		39,023		3,778		-		42,801

Investments:
Commercial Paper		-		5,147		-		5,147
United States Treasury securities		228,443		-		-		228,443
Corporate Bonds		-		54,159		-		54,159
Agency Bonds		-		7,713		-		7,713
		228,443		67,019		-		295,462

Total assets	$	267,466	$	70,797	$	-	$	338,263

Liabilities:
Warrant liability	$	-	$	-	$	815	$	815
Total liabilities	$	-	$	-	$	815	$	815

	Fair Value Measurements as of
	December 31, 2022 Using:
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market mutual funds	$	90,527	$	-	$	-	$	90,527
Commercial Paper		-		3,899		-		3,899
United States Treasury Securities		3,848		-		-		3,848
Corporate Bonds		-		8,618		-		8,618
		94,375		12,517		-		106,892

Investments:
Commercial Paper		-		1,151		-		1,151
United States Treasury securities		189,444		-		-		189,444
Corporate Bonds		-		60,905		-		60,905
Agency Bonds		-		7,653		-		7,653
		189,444		69,709		-		259,153

Total assets	$	283,819	$	82,226	$	-	$	366,045

Liabilities:
Warrant liability	$	-	$	-	$	1,512	$	1,512
Total liabilities	$	-	$	-	$	1,512	$	1,512

The Company classifies its money market mutual funds and U.S. Treasury securities as Level 1 assets under the fair value hierarchy, as these assets have been valued using quoted market prices in active markets without any valuation adjustment. The Company classifies its Commercial Paper and Corporate and Agency Bonds as Level 2 assets as these assets are not traded in an active market and have been valued through a third-party pricing service based on quoted prices for similar assets.

The reconciliation of the Company’s warrant liability, which is recorded as part of Other Liabilities in the consolidated balance sheets, measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows:

	Warrant Liability
Balance, December 31, 2022	$	1,512
Fair value adjustments		(697	)
Balance, March 31, 2023	$	815

The Company utilizes a Black-Scholes model to value the warrant liability (see Note 10 “Warrants”) at each reporting period, with changes in fair value recognized in the consolidated statements of operations. The estimated fair value of the warrant liability is determined using Level 3 inputs. Inherent in an options pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the expected volatility of its common stock based on historical volatility of a peer group, considering the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the valuation date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.

The fair value of the warrant liability has been estimated with the following assumptions:

	March 31, 2023			December 31, 2022
Stock price	$	17.13		$	18.39
Exercise price	$	65.23		$	65.23
Expected volatility		67.38	%		71.25	%
Risk-free interest rate		4.04	%		4.14	%
Expected dividend yield		-			-
Expected life (years)		2.07			2.39
Fair value per warrant	$	1.32		$	2.45

Property and Equipment, Net

3 Months Ended

Mar. 31, 2023

Property and Equipment, Net [Abstract]

Property and Equipment, Net

5.	Property and Equipment, Net

The Company’s property and equipment consisted of the following:

	March 31,			December 31,
	2023			2022
Laboratory equipment	$	23,317		$	21,905
Machinery and equipment		11,443			11,326
Computer equipment		244			244
Furniture and fixtures		2,216			2,135
Leasehold improvements		1,694			589
Internal use software		1,903			1,903
		40,817			38,102
Less: accumulated depreciation and amortization		(10,229	)		(9,093	)
	$	30,588		$	29,009

During the three months ended March 31, 2023 and 2022, the Company recognized $1.1 million and $0.8 million of depreciation and amortization expense, respectively.

Intangible Assets and Goodwill

3 Months Ended

Mar. 31, 2023

Intangible Assets and Goodwill [Abstract]

Intangible Assets and Goodwill

6.	Intangible Assets and Goodwill

The Company’s indefinite lived intangible assets consists of acquired IPR&D asset and a mice colony model received from the acquisition of Renovacor.

Intangible assets as of March 31, 2023 and December 31, 2022 are summarized as follows:

	Gross Carrying Value		Accumulated Amortization		Intangible Assets, Net
In process research & development	$	25,150	$	-	$	25,150
Mice colony model		574		-		574
Total intangible assets	$	25,724	$	-	$	25,724

The gross carrying value of intangible assets was due to the acquisition of Renovacor (see Note 14 “Renovacor Acquisition”).

The carrying value of Goodwill was $39.2 million as of March 31, 2023 and included $8.3 million as a result of the acquisition of Renovacor (see Note 14 “Renovacor Acquisition”).

Accounts Payable and Accrued Expenses

3 Months Ended

Mar. 31, 2023

Accounts Payable and Accrued Expenses [Abstract]

Accounts Payable and Accrued Expenses

7.	Accounts Payable and Accrued Expenses

As of March 31, 2023 and December 31, 2022, the Company’s accounts payable and accrued expenses consisted of the following:

	March 31,		December 31,
	2023		2022
Research and development	$	17,536	$	19,100
Employee compensation		4,199		10,006
Property and equipment		1,794		2,095
Professional fees		2,813		1,436
Acquisition related expenses		-		1,153
Government grant payable		597		597
Other		1,670		2,273
	$	28,609	$	36,660

Stockholders' Equity

3 Months Ended

Mar. 31, 2023

Stockholders' Equity [Abstract]

Stockholders' Equity

8.	Stockholders’ Equity

At-the-Market Offering Program

On February 28, 2022, the Company entered into the Sales Agreement with Cowen with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares through Cowen as its sales agent. The shares to be offered and sold under the Sales Agreement, if any, will be offered and sold pursuant to the Company’s shelf registration statement on Form S-3. The Company filed a prospectus supplement with the SEC on February 28, 2022 in connection with the offer and sale of the shares pursuant to the Sales Agreement. The Company will pay Cowen a cash commission of 3.0% of gross proceeds from the sale of the shares pursuant to the Sales Agreement. The Company has provided Cowen with customary indemnification and contribution rights. The Company reimbursed Cowen for certain expenses incurred in connection with the Sales Agreement. Through March 31, 2023, the Company sold 4.2 million shares under the at-the-market offering program for gross proceeds of $65.8 million, less commissions of $2.0 million for net proceeds of $63.8 million. During the three months ended March 31, 2023, the Company sold 0.9 million shares under the at-the-market offering program for gross proceeds of $17.8 million, less commission of $0.6 million for net proceeds of $17.2 million.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Stock Based Compensation

3 Months Ended

Mar. 31, 2023

Stock Based Compensation [Abstract]

Stock Based Compensation

9.	Stock Based Compensation

Stock Option Valuation

The weighted average assumptions that the Company used in the Black-Scholes pricing model to determine the fair value of the stock options granted to employees, non-employees and directors were as follows:

	Three Months Ended March 31,
	2023			2022
Risk-free interest rate		4.02	%		1.88	%
Expected term (in years)		5.88			5.86
Expected volatility		73.54	%		74.07	%
Expected dividend yield		0.00	%		0.00	%
Exercise price	$	20.17		$	17.85
Fair value of common stock	$	20.17		$	17.85

The following table summarizes stock option activity for the three months ended March 31, 2023, under the Second Amended and Restated 2014 Stock Option and Incentive Plan:

				Weighted			Weighted
				Average			Average		Aggregate
	Number of			Exercise			Contractual		Intrinsic
	Shares			Price			Term (Years)		Value

Outstanding as of December 31, 2022		13,138,870			$	14.52		5.46		$	118,767
Granted		1,792,097				20.36		6.86
Exercised		(88,429	)			12.59					631
Cancelled		(191,148	)			33.99
Outstanding as of March 31, 2023		14,651,390			$	14.99		5.85		$	97,263

Options vested and exercisable as of March 31, 2023		10,586,141			$	12.60		4.52		$	92,808
Options unvested as of March 31, 2023		4,065,249			$	21.24		9.32		$	4,455

The weighted average grant-date fair value per share of stock options granted during the three months ended March 31, 2023, and 2022 was $13.50 and $11.60, respectively.

The total fair value of options vested during the three months ended March 31, 2023 and 2022 was $11.4 million and $12.5 million, respectively.

Restricted Stock Units (“RSU”)

The following table summarizes the Company’s RSU activity for the three months ended March 31, 2023:

				Weighted
				Average
	Number of			Grant Date
	Shares			Fair Value

Unvested as of December 31, 2022		992,874			$	16.49
Granted		764,204				20.23
Vested⁽¹⁾		(126,145	)			17.37
Forfeited		(8,476	)			17.19
Unvested as of March 31, 2023		1,622,457			$	18.18

(1) Common stock issued is net of 85 shares related to taxes.

Stock-based Compensation

Stock-based compensation expense recognized by award type was as follows:

	Three Months Ended March 31,
	2023		2022

Stock options	$	6,985	$	5,961
Restricted stock units		1,930		309
Total stock-based compensation expense	$	8,915	$	6,270

Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows:

	Three Months Ended March 31,
	2023		2022

Research and development	$	3,819	$	2,318
General and administrative		5,096		3,952
Total stock-based compensation expense	$	8,915	$	6,270

As of March 31, 2023, the Company had an aggregate of $75.4 million of unrecognized stock-based compensation expense related to both stock options and RSU grants, which is expected to be recognized over the weighted average period of 1.52 years.

Warrants

3 Months Ended

Mar. 31, 2023

Warrants [Abstract]

Warrants

10.

Warrants

A summary of the warrants outstanding as of March 31, 2023 is as follows:

Exercise Price	Outstanding		Grant/Assumption Date	Expiration Date
24.42		7,051	June 28, 2013	June 28, 2023
57.11		603,386	December 21, 2020	December 21, 2030
33.63		301,291	August 9, 2021	August 9, 2031
22.51		153,155	December 17, 2021	December 17, 2031
22.51		153,155	December 17, 2021	December 17, 2031
65.23		617,050	December 1, 2022	April 23, 2025
65.23		760,086	December 1, 2022	December 1, 2026
Total		2,595,174

The following table below is a summary of changes in warrants to purchase common stock for the three months ended March 31, 2023:

	Number of Warrant Shares Outstanding and Exercisable			Exercise Price per Share
Balance as of December 31, 2022		2,721,267
Granted		-
Exercised		(126,093	)	$	0.06
Balance as of March 31, 2023		2,595,174

Assumed Renovacor Public Warrants

In conjunction with the Renovacor acquisition (see Note 14 “Renovacor Acquisition”), Rocket assumed pre-acquisition public warrants (“Public Warrants”) that were converted into Rocket warrants with a right to purchase 760,086 of Rocket common shares at an exercise price of $65.23 per share.

The Company determined that the Public Warrants met all of the criteria for equity classification. Accordingly, upon closing of the Merger, the Public Warrants were recorded as a component of additional paid-in capital of $3.4 million.

Assumed Renovacor Private Warrants

In conjunction with the Renovacor acquisition (see Note 14 “Renovacor Acquisition”), Rocket assumed pre-acquisition private warrants (“Private Warrants”) that were converted into Rocket warrants with a right to purchase 617,050 of Rocket common shares at an exercise price of $65.23 per share.

The Company determined that the Private Warrants did not meet all of the criteria for equity classification. Accordingly, the Company classifies the Private Warrants as derivative liabilities in its consolidated balance sheets. The Company measures the fair value of the warrants at the end of each reporting period and recognizes changes in the fair value from the prior period in the Company’s operating results for the current period. See Note 4 for discussion of fair value measurement of the warrant liabilities.

Assumed Renovacor Pre-Funded Warrants

In conjunction with the Renovacor acquisition (see Note 14 “Renovacor Acquisition”), Rocket assumed pre-funded warrants (“Pre-Funded Warrants”) that were converted into Rocket warrants with a right to purchase 126,093 of Rocket common shares at an exercise price of $0.06 per share. These warrants were exercised in January 2023.

Net Loss Per Share

3 Months Ended

Mar. 31, 2023

Net Loss Per Share [Abstract]

Net Loss Per Share

11.	Net Loss Per Share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:

	Three Months Ended March 31,
	2023			2022
Numerator:
Net loss attributable to common stockholders	$	(58,335	)	$	(42,982	)
Denominator:
Weighted-average common shares outstanding - basic and diluted		79,453,519			64,509,721
Net loss per share attributable to common stockholders - basic and diluted	$	(0.73	)	$	(0.67	)

The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

	Three Months Ended March 31,
	2023		2022
Warrants exercisable for common shares		2,595,174		1,218,038
Restricted stock units convertible for common shares		1,622,457		457,709
Options to purchase common shares		14,651,390		12,047,299
		18,869,021		13,723,046

Commitments and Contingencies

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies [Abstract]

Commitments and Contingencies

12.	Commitments and Contingencies

The Company determines if an arrangement is a lease at inception. Operating and finance leases are presented in the Company’s consolidated balance sheet as right-of-use assets from leases, current lease liabilities and long-term lease liabilities. Certain of the Company’s lease agreements contain renewal options; however, the Company does not recognize right-of-use assets or lease liabilities for renewal periods unless it is determined that the Company is reasonably certain of renewing the lease at inception or when a triggering event occurs. As the Company’s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments using an estimate of the Company’s collateralized borrowing rate for debt with a similar term. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the biotechnology industry. Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component. Some of the Company’s lease agreements contain rent escalation clauses (including index-based escalations). For operating leases, the Company recognizes the minimum rental expense on a straight-line basis based on the fixed components of a lease arrangement. The Company will amortize this expense over the term of the lease beginning with the lease commencement date. Variable lease components represent amounts that are not fixed in nature and are not tied to an index or rate and are recognized as incurred.

Finance Lease

The Company has a lease for a facility in Cranbury, New Jersey, consisting of 103,720 square feet of space including areas for offices, process development, research, and development laboratories and 50,000 square feet dedicated to AAV Current Good Manufacturing Practice (“cGMP”) manufacturing facilities to support the Company’s pipeline (such lease, as amended, the “NJ Lease Agreement”). The NJ Lease Agreement has a 15-year term from September 1, 2019, with an option to renew for two consecutive five-year renewal terms.

Estimated rent payments for the NJ Lease Agreement are $1.2 million per annum, payable in monthly installments, depending upon the nature of the leased space, and subject to annual base rent increases of 3%. The total commitment under the lease is estimated to be approximately $29.3 million over the 15-year term of the lease. The Company paid a cash security deposit of $0.3 million to the landlord in connection with the NJ Lease Agreement which has been reflected in deposits in the consolidated balance sheets as of March 31, 2023 and December 31, 2022.

Operating Leases

On June 7, 2018, the Company entered into a three-year lease agreement for office space in the Empire State Building in New York, NY (the “ESB Lease Agreement”). In connection with the ESB Lease Agreement, the Company established an irrevocable standby letter of credit (the “Empire LOC”) for $0.9 million. On March 26, 2021, the Company entered in Amendment No. 1 to the ESB Lease Agreement (“ESB Lease Amendment”) that extended the term of the lease agreement to June 30, 2024, reduced the rent payments going forward, and reduced the Empire LOC to $0.8 million. The Empire LOC serves as the Company’s security deposit on the lease in which the landlord is the beneficiary and expires August 29, 2024. The Company has a certificate of deposit of $0.8 million with a bank as collateral for the Empire LOC which is classified as part of restricted cash in the consolidated balance sheets as of March 31, 2023 and December 31, 2022.

On January 4, 2018, in connection with the Reverse Merger with Inotek, the Company assumed an operating lease for Inotek’s former headquarters in Lexington, Massachusetts, with a term which ended on February 28, 2023. In July 2018, the Company signed an agreement to sublease a portion of the Lexington, Massachusetts space and in September 2018, the Company signed an agreement to sublease the remaining portion of the Lexington, Massachusetts space. Rental income received under the sublease agreement totaled $0.1 million for the three months ended March 31, 2023 and 2022. These amounts are netted against rent expense in the consolidated statements of operations for the three months ended March 31, 2023 and 2022. A security deposit of $0.2 million was returned to the Company in April 2023 and is reflected in other current assets as of March 31, 2023.

On December 1, 2022, in connection with the Renovacor acquisition (see Note 14 “Renovacor Acquisition”), Rocket acquired the Renovacor operating leases for space at facilities in Hopewell, New Jersey and Cambridge, Massachusetts with remaining lease terms of approximately 10.25 and 1.3 years, respectively. As of March 31, 2023, lease commencement dates have occurred for all leases and the Company recognized total right-of-use assets of $3.8 million with corresponding total lease liabilities of $3.6 million. The Company intends to sublease both premises through the remainder of their lease terms.

Rent expense was $0.4 million and $0.3 million for the three months ended March 31, 2023 and 2022, respectively.

The total restricted cash balance for the Company’s operating and finance leases as of each of March 31, 2023 and December 31, 2022 was $0.8 million.

Lease cost	March 31, 2023
Operating lease cost	$	358
Finance lease cost
Amortization of right of use assets		538
Interest on lease liabilities		468
Total lease cost	$	1,364

The following table summarizes the future lease payments of the Company’s operating and finance lease liabilities on an undiscounted cash flow basis and a reconciliation to the operating and finance lease liabilities as of March 31, 2023:

Fiscal Year Ending December 31,	March 31, 2023
2023 (nine months)		869
2024		798
2025		538
2026		545
2027		506
Thereafter		2,941
Total lease payments	$	6,197
Less: interest		(1,842	)
Total operating lease liabilities	$	4,355

Fiscal Year Ending December 31,	March 31, 2023
2023 (nine months)		1,305
2024		1,791
2025		1,856
2026		1,912
2027		1,969
Thereafter		43,032
Total lease payments	$	51,865
Less: interest		(30,823	)
Total finance lease liability	$	21,042

Leases	March 31, 2023
Operating right-of-use assets	$	4,369

Operating current lease liabilities		849
Operating noncurrent lease liabilities		3,506
Total operating lease liabilities	$	4,355

Finance right-of-use assets	$	46,133

Finance current lease liability		1,748
Finance noncurrent lease liability		19,294
Total finance lease liability	$	21,042

Other information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	261
Cash flows from finance lease	$	431
Weighted-average remaining lease term - operating leases	8.2 years
Weighted-average remaining lease term - finance lease	21.4 years
Weighted-average discount rate - operating leases		8.08	%
Weighted-average discount rate - finance lease		8.96	%

Litigation

From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Although the results of litigation and claims cannot be predicted with certainty, the Company does not believe it is party to any other claim or litigation the outcome of which, if determined adversely to the Company, would individually or in the aggregate be reasonably expected to have a material adverse effect on its business. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors.

Indemnification Arrangements

Pursuant to its bylaws and as permitted under Delaware law, the Company has indemnification obligations to directors, officers, employees or agents of the Company or anyone serving in these capacities. The maximum potential amount of future payments the Company could be required to pay is unlimited. The Company has insurance that reduces its monetary exposure and would enable it to recover a portion of any future amounts paid. As a result, the Company believes that the estimated fair value of these indemnification commitments is minimal.

Throughout the normal course of business, the Company has agreements with vendors that provide goods and services required by the Company to run its business. In some instances, vendor agreements include language that requires the Company to indemnify the vendor from certain damages caused by the Company’s use of the vendor’s goods and/or services. The Company has insurance that would allow it to recover a portion of any future amounts that could arise from these indemnifications. As a result, the Company believes that the estimated fair value of these indemnification commitments is minimal.

Agreements Related to Intellectual Property

3 Months Ended

Mar. 31, 2023

13.	Agreements Related to Intellectual Property

The Company, directly and through its subsidiary Spacecraft Seven, LLC, has various license and research and collaboration arrangements. The transactions principally resulted in the acquisition of rights to intellectual property which is in the preclinical phase and has not been tested for safety or feasibility. In all cases, the Company did not acquire tangible assets, processes, protocols, or operating systems. The Company expenses the acquired intellectual property rights as of the acquisition date on the basis that the cost of intangible assets purchased from others for use in research and development activities has no alternative future uses.

Renovacor Acquisition

3 Months Ended

Mar. 31, 2023

Renovacor Acquisition [Abstract]

Renovacor Acquisition

14.	Renovacor Acquisition

On September 19, 2022, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Renovacor, a Delaware corporation pursuant to which, on December 1, 2022, the Company acquired Renovacor (the “Renovacor Acquisition”). On December 1, 2022, pursuant to the terms of the Merger Agreement, (i) Merger Sub I merged with and into the Company (the “First Merger”) and (ii) the Company, as the surviving company of the First Merger merged with and into Merger Sub II, with Merger Sub II surviving the Second Merger. Subject to the terms and conditions of the Merger Agreement, at the closing of the Renovacor Acquisition each share of Renovacor’s common stock outstanding immediately prior to the effective time of the First Merger were canceled and converted into the right to receive 0.1763 (the “Exchange Ratio”) of fully paid and non-assessable shares of the Company common stock, which was determined on the basis of the exchange formula set forth in the Merger Agreement that was subject to adjustment depending on the level of the Renovacor’s net cash at the closing. Prior to the market opening on December 1, 2022, Renovacor shares ceased to trade on NYSE and upon the closing of the acquisition, Renovacor’s outstanding common stock were converted into 3,391,976 shares of Rocket common stock.

Total consideration for the Renovacor Acquisition was $72.3 million, consisting of $62.4 million for common stock outstanding, $2.7 million for the portion of equity compensation attributable to the pre-combination service period, and $7.2 million for assumed warrants. The consideration was based on the estimated fair values on the acquisition date of (i) 3,391,976 common shares issued for shares outstanding for common shares of Renovacor, (ii) estimated fair value of employee stock options to acquire 367,852 common shares of the Company, (iii) 28,798 common shares issued for employee time-vesting RSUs, and (iv) warrants to acquire 1,503,229 common shares (see Note 10 “Warrants”).

The total consideration for the acquisition of Renovacor of $72.3 million consisted of the following:

	Shares		Value		Total
Stock consideration		3,391,976	$	18.39	$	62,378
Cash consideration⁽¹⁾						29
Stock options		367,852				2,163
Time-vesting RSUs		28,798				512
Assumed warrants⁽²⁾		1,503,229				7,183
Total consideration		5,291,855			$	72,265

(1)	Represents consideration paid for cash in lieu of fractional shares.

(2)	Assumed Renovacor Warrants of $7,183 with $5,671 classified as equity and $1,512 classified as liabilities.

The acquisition has been accounted for as a business combination using the acquisition method of accounting which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date and that the fair value of acquired IPR&D assets are classified as indefinite-life assets until the successful completion or abandonment of the associated research and development efforts.

The preliminary purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the acquisition date based on their respective preliminary fair values summarized below:

Working capital⁽¹⁾	$	(5,210	)
Cash and cash equivalents		42,755
Property and equipment		1,414
Operating lease right-of-use assets		1,161
Other non-current assets		113
IPR&D		25,150
Other intangible asset		574
Operating lease liability		(970	)
Deferred tax liability		(1,061	)
Net assets acquired		63,926
Goodwill		8,339
Purchase consideration	$	72,265

(1)	Includes other receivables, prepaid expenses, account payable and accrued liabilities.

The excess of purchase price over the fair value of amounts assigned to identifiable assets acquired and liabilities assumed represents the goodwill amount of $8.3 million resulting from the acquisition. The goodwill recorded as part of the acquisition is primarily attributable to the broadening of the Company’s portfolio and research capabilities, deferred taxes and the assembled workforce. The goodwill attributable to the acquisition has been recorded as a non-current asset in the Company’s consolidated balance sheet and is not amortized, but subject to review for impairment annually.

CIRM Grants

3 Months Ended

Mar. 31, 2023

CIRM Grants [Abstract]

CIRM Grants

15.	CIRM Grants

LAD-1 CIRM Grant

On April 30, 2019, the California Institute for Regenerative Medicine (“CIRM”) awarded the Company up to $7.5 million under a CLIN2 grant award to support the clinical development of its LV-based gene therapy for RP-L201. Proceeds from the grant will help fund clinical trial costs as well as manufactured drug product for Phase 1/2 patients enrolled at the U.S. clinical site, University of California, Los Angeles (“UCLA”) Mattel Children’s Hospital, led by principal investigator Donald Kohn, M.D., UCLA Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. Through March 31, 2023, the Company has received $5.9 million in total RP-L201 grants from CIRM. No additional milestones were achieved as of March 31, 2023.

Related Party Transactions

3 Months Ended

Mar. 31, 2023

Related Party Transactions

16.	Related Party Transactions

In October 2020, the Company entered into a consulting agreement with the spouse of one of the Company’s executive officers for information technology advisory services. In exchange for the services provided under the agreement, the Company granted 10,000 restricted stock units which vest over a three-year period.

401(k) Savings Plan

3 Months Ended

Mar. 31, 2023

401(k) Savings Plan [Abstract]

401(k) Savings Plan

17.	401(k) Savings Plan

The Company has a defined contribution savings plan (the “Plan”) under Section 401(k) of the Internal Revenue Code of 1986. This Plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Company contributions to the Plan may be made at the discretion of the Company’s Board of Directors. The Company has elected the safe harbor match of 4% of employee contributions to the Plan, subject to certain limitations. The Company’s matching contribution for the three months ended March 31, 2023 and 2022, was $0.3 million and $0.2 million, respectively.

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2023

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies [Abstract]

Basis of Presentation

Significant Accounting Policies

Principles of Consolidation

Use of Estimates

Cash, Cash Equivalents and Restricted Cash

	March 31,		December 31,
	2023		2022
Cash and cash equivalents	$	64,579	$	140,517
Restricted cash		1,340		1,340
	$	65,919	$	141,857

Concentrations of Credit Risk and Off-balance Sheet Risk

Concentrations of credit risk and off-balance sheet risk

Investments

Intangible Assets

Fair Value Measurements

•

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

•

Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

•

Level 3—Valuations that require inputs that reflect the Company’s own assumptions that are both significant to the fair value measurement and unobservable.

Warrants

Stock-Based Compensation

Income Taxes

Recent Accounting Pronouncements

There were no recent accounting pronouncements that impacted the Company, or which had a significant effect on the consolidated financial statements.

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2023

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies [Abstract]

Cash, Cash Equivalents and Restricted Cash

	March 31,		December 31,
	2023		2022
Cash and cash equivalents	$	64,579	$	140,517
Restricted cash		1,340		1,340
	$	65,919	$	141,857

Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2023

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments Measured on Recurring Basis

	Fair Value Measurements as of
	March 31, 2023 Using:
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market mutual funds	$	31,353	$	-	$	-	$	31,353
Corporate Bonds		-		3,778		-		3,778
United States Treasury securities		7,670		-		-		7,670
		39,023		3,778		-		42,801

Investments:
Commercial Paper		-		5,147		-		5,147
United States Treasury securities		228,443		-		-		228,443
Corporate Bonds		-		54,159		-		54,159
Agency Bonds		-		7,713		-		7,713
		228,443		67,019		-		295,462

Total assets	$	267,466	$	70,797	$	-	$	338,263

Liabilities:
Warrant liability	$	-	$	-	$	815	$	815
Total liabilities	$	-	$	-	$	815	$	815

	Fair Value Measurements as of
	December 31, 2022 Using:
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market mutual funds	$	90,527	$	-	$	-	$	90,527
Commercial Paper		-		3,899		-		3,899
United States Treasury Securities		3,848		-		-		3,848
Corporate Bonds		-		8,618		-		8,618
		94,375		12,517		-		106,892

Investments:
Commercial Paper		-		1,151		-		1,151
United States Treasury securities		189,444		-		-		189,444
Corporate Bonds		-		60,905		-		60,905
Agency Bonds		-		7,653		-		7,653
		189,444		69,709		-		259,153

Total assets	$	283,819	$	82,226	$	-	$	366,045

Liabilities:
Warrant liability	$	-	$	-	$	1,512	$	1,512
Total liabilities	$	-	$	-	$	1,512	$	1,512

Changes in Level 3 Liabilities Measured at Fair Value

	Warrant Liability
Balance, December 31, 2022	$	1,512
Fair value adjustments		(697	)
Balance, March 31, 2023	$	815

Level 3 Fair Value of the Private Warrants

The fair value of the warrant liability has been estimated with the following assumptions:

	March 31, 2023			December 31, 2022
Stock price	$	17.13		$	18.39
Exercise price	$	65.23		$	65.23
Expected volatility		67.38	%		71.25	%
Risk-free interest rate		4.04	%		4.14	%
Expected dividend yield		-			-
Expected life (years)		2.07			2.39
Fair value per warrant	$	1.32		$	2.45

Property and Equipment, Net (Tables)

3 Months Ended

Mar. 31, 2023

Property and Equipment, Net [Abstract]

Property and Equipment

The Company’s property and equipment consisted of the following:

	March 31,			December 31,
	2023			2022
Laboratory equipment	$	23,317		$	21,905
Machinery and equipment		11,443			11,326
Computer equipment		244			244
Furniture and fixtures		2,216			2,135
Leasehold improvements		1,694			589
Internal use software		1,903			1,903
		40,817			38,102
Less: accumulated depreciation and amortization		(10,229	)		(9,093	)
	$	30,588		$	29,009

Intangible Assets and Goodwill (Tables)

3 Months Ended

Mar. 31, 2023

Intangible Assets and Goodwill [Abstract]

Summary of Intangible Assets

Intangible assets as of March 31, 2023 and December 31, 2022 are summarized as follows:

	Gross Carrying Value		Accumulated Amortization		Intangible Assets, Net
In process research & development	$	25,150	$	-	$	25,150
Mice colony model		574		-		574
Total intangible assets	$	25,724	$	-	$	25,724

Accounts Payable and Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2023

Accounts Payable and Accrued Expenses [Abstract]

Accounts Payable and Accrued Expenses

As of March 31, 2023 and December 31, 2022, the Company’s accounts payable and accrued expenses consisted of the following:

	March 31,		December 31,
	2023		2022
Research and development	$	17,536	$	19,100
Employee compensation		4,199		10,006
Property and equipment		1,794		2,095
Professional fees		2,813		1,436
Acquisition related expenses		-		1,153
Government grant payable		597		597
Other		1,670		2,273
	$	28,609	$	36,660

Stock Based Compensation (Tables)

3 Months Ended

Mar. 31, 2023

Stock Based Compensation [Abstract]

Weighted-Average Assumptions for Stock Options

	Three Months Ended March 31,
	2023			2022
Risk-free interest rate		4.02	%		1.88	%
Expected term (in years)		5.88			5.86
Expected volatility		73.54	%		74.07	%
Expected dividend yield		0.00	%		0.00	%
Exercise price	$	20.17		$	17.85
Fair value of common stock	$	20.17		$	17.85

Stock Option Activity

The following table summarizes stock option activity for the three months ended March 31, 2023, under the Second Amended and Restated 2014 Stock Option and Incentive Plan:

				Weighted			Weighted
				Average			Average		Aggregate
	Number of			Exercise			Contractual		Intrinsic
	Shares			Price			Term (Years)		Value

Outstanding as of December 31, 2022		13,138,870			$	14.52		5.46		$	118,767
Granted		1,792,097				20.36		6.86
Exercised		(88,429	)			12.59					631
Cancelled		(191,148	)			33.99
Outstanding as of March 31, 2023		14,651,390			$	14.99		5.85		$	97,263

Options vested and exercisable as of March 31, 2023		10,586,141			$	12.60		4.52		$	92,808
Options unvested as of March 31, 2023		4,065,249			$	21.24		9.32		$	4,455

RSU Activity

The following table summarizes the Company’s RSU activity for the three months ended March 31, 2023:

				Weighted
				Average
	Number of			Grant Date
	Shares			Fair Value

Unvested as of December 31, 2022		992,874			$	16.49
Granted		764,204				20.23
Vested⁽¹⁾		(126,145	)			17.37
Forfeited		(8,476	)			17.19
Unvested as of March 31, 2023		1,622,457			$	18.18

(1) Common stock issued is net of 85 shares related to taxes.

Stock-Based Compensation Expense by Award Type

Stock-based compensation expense recognized by award type was as follows:

	Three Months Ended March 31,
	2023		2022

Stock options	$	6,985	$	5,961
Restricted stock units		1,930		309
Total stock-based compensation expense	$	8,915	$	6,270

Stock-Based Compensation Expense

Stock-based compensation expense by classification included within the consolidated statements of operations and comprehensive loss was as follows:

	Three Months Ended March 31,
	2023		2022

Research and development	$	3,819	$	2,318
General and administrative		5,096		3,952
Total stock-based compensation expense	$	8,915	$	6,270

Warrants (Tables)

3 Months Ended

Mar. 31, 2023

Warrants [Abstract]

Warrants Outstanding and Changes in Warrants to Purchase Common Stock

A summary of the warrants outstanding as of March 31, 2023 is as follows:

Exercise Price	Outstanding		Grant/Assumption Date	Expiration Date
24.42		7,051	June 28, 2013	June 28, 2023
57.11		603,386	December 21, 2020	December 21, 2030
33.63		301,291	August 9, 2021	August 9, 2031
22.51		153,155	December 17, 2021	December 17, 2031
22.51		153,155	December 17, 2021	December 17, 2031
65.23		617,050	December 1, 2022	April 23, 2025
65.23		760,086	December 1, 2022	December 1, 2026
Total		2,595,174

The following table below is a summary of changes in warrants to purchase common stock for the three months ended March 31, 2023:

	Number of Warrant Shares Outstanding and Exercisable			Exercise Price per Share
Balance as of December 31, 2022		2,721,267
Granted		-
Exercised		(126,093	)	$	0.06
Balance as of March 31, 2023		2,595,174

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2023

Net Loss Per Share [Abstract]

Basic and Diluted Net Loss Per Share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:

	Three Months Ended March 31,
	2023			2022
Numerator:
Net loss attributable to common stockholders	$	(58,335	)	$	(42,982	)
Denominator:
Weighted-average common shares outstanding - basic and diluted		79,453,519			64,509,721
Net loss per share attributable to common stockholders - basic and diluted	$	(0.73	)	$	(0.67	)

Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share

	Three Months Ended March 31,
	2023		2022
Warrants exercisable for common shares		2,595,174		1,218,038
Restricted stock units convertible for common shares		1,622,457		457,709
Options to purchase common shares		14,651,390		12,047,299
		18,869,021		13,723,046

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies [Abstract]

Lease Cost

Lease cost	March 31, 2023
Operating lease cost	$	358
Finance lease cost
Amortization of right of use assets		538
Interest on lease liabilities		468
Total lease cost	$	1,364

Future Lease Payments of Operating Lease Liabilities

Fiscal Year Ending December 31,	March 31, 2023
2023 (nine months)		869
2024		798
2025		538
2026		545
2027		506
Thereafter		2,941
Total lease payments	$	6,197
Less: interest		(1,842	)
Total operating lease liabilities	$	4,355

Future Lease Payments of Finance Lease Liability

Fiscal Year Ending December 31,	March 31, 2023
2023 (nine months)		1,305
2024		1,791
2025		1,856
2026		1,912
2027		1,969
Thereafter		43,032
Total lease payments	$	51,865
Less: interest		(30,823	)
Total finance lease liability	$	21,042

Balance Sheet Information Related to Leases

Leases	March 31, 2023
Operating right-of-use assets	$	4,369

Operating current lease liabilities		849
Operating noncurrent lease liabilities		3,506
Total operating lease liabilities	$	4,355

Finance right-of-use assets	$	46,133

Finance current lease liability		1,748
Finance noncurrent lease liability		19,294
Total finance lease liability	$	21,042

Other information
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	261
Cash flows from finance lease	$	431
Weighted-average remaining lease term - operating leases	8.2 years
Weighted-average remaining lease term - finance lease	21.4 years
Weighted-average discount rate - operating leases		8.08	%
Weighted-average discount rate - finance lease		8.96	%

Renovacor Acquisition (Tables)

3 Months Ended

Mar. 31, 2023

Renovacor Acquisition [Abstract]

Total Consideration for Acquisition

The total consideration for the acquisition of Renovacor of $72.3 million consisted of the following:

	Shares		Value		Total
Stock consideration		3,391,976	$	18.39	$	62,378
Cash consideration⁽¹⁾						29
Stock options		367,852				2,163
Time-vesting RSUs		28,798				512
Assumed warrants⁽²⁾		1,503,229				7,183
Total consideration		5,291,855			$	72,265

(1)	Represents consideration paid for cash in lieu of fractional shares.

(2)	Assumed Renovacor Warrants of $7,183 with $5,671 classified as equity and $1,512 classified as liabilities.

Purchase Price allocation of Assets Acquired and Liabilities Assumed

Working capital⁽¹⁾	$	(5,210	)
Cash and cash equivalents		42,755
Property and equipment		1,414
Operating lease right-of-use assets		1,161
Other non-current assets		113
IPR&D		25,150
Other intangible asset		574
Operating lease liability		(970	)
Deferred tax liability		(1,061	)
Net assets acquired		63,926
Goodwill		8,339
Purchase consideration	$	72,265

(1)	Includes other receivables, prepaid expenses, account payable and accrued liabilities.

Nature of Business (Details)	3 Months Ended
Nature of Business (Details)	Mar. 31, 2023 Program
Nature of Business [Abstract]
Number of clinical-stage programs	3

Risks and Liquidity (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Feb. 28, 2022
Risks and Liquidity [Abstract]
Accumulated deficit	$ (772,110)		$ (713,775)
Cash, cash equivalents and investments	$ 360,000
Shareholders' Equity Disclosure [Abstract]
Common stock, par value (in dollars per share)	$ 0.01		$ 0.01
Issuance of common stock, net of issuance costs	$ 17,222	$ 0
At-the-Market Offering [Member]
Shareholders' Equity Disclosure [Abstract]
Common stock shares issued and sold (in shares)	0.9
Issuance of common stock, net of issuance costs	$ 17,200
At-the-Market Offering [Member] \| Cowen and Company, LLC [Member]
Shareholders' Equity Disclosure [Abstract]
Common stock, par value (in dollars per share)				$ 0.01
Common stock shares issued and sold (in shares)	4.2
Issuance of common stock, net of issuance costs	$ 63,800
At-the-Market Offering [Member] \| Cowen and Company, LLC [Member] \| Maximum [Member]
Shareholders' Equity Disclosure [Abstract]
Aggregate offering price				$ 200,000

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Cash, Cash Equivalents and Restricted Cash [Abstract]
Cash and cash equivalents	$ 64,579	$ 140,517
Restricted cash	1,340	1,340
Total	$ 65,919	$ 141,857	$ 131,895	$ 234,037

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies, Investments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Investments [Abstract]
Net unrealized gain (loss) on investments	$ 267	$ (468)

Fair Value of Financial Instruments, Measured on Recurring Basis (Details) - Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets [Abstract]
Cash equivalents	$ 42,801	$ 106,892
Investments	295,462	259,153
Fair value of financial instruments	338,263	366,045
Liabilities [Abstract]
Total liabilities	815	1,512
Warrant Liability [Member]
Liabilities [Abstract]
Total liabilities	815	1,512
Money Market Mutual Funds [Member]
Assets [Abstract]
Cash equivalents	31,353	90,527
Commercial Paper [Member]
Assets [Abstract]
Cash equivalents		3,899
Investments	5,147	1,151
United States Treasury Securities [Member]
Assets [Abstract]
Cash equivalents	7,670	3,848
Investments	228,443	189,444
Corporate Bonds [Member]
Assets [Abstract]
Cash equivalents	3,778	8,618
Investments	54,159	60,905
Agency Bonds [Member]
Assets [Abstract]
Investments	7,713	7,653
Level 1 [Member]
Assets [Abstract]
Cash equivalents	39,023	94,375
Investments	228,443	189,444
Fair value of financial instruments	267,466	283,819
Liabilities [Abstract]
Total liabilities	0	0
Level 1 [Member] \| Warrant Liability [Member]
Liabilities [Abstract]
Total liabilities	0	0
Level 1 [Member] \| Money Market Mutual Funds [Member]
Assets [Abstract]
Cash equivalents	31,353	90,527
Level 1 [Member] \| Commercial Paper [Member]
Assets [Abstract]
Cash equivalents		0
Investments	0	0
Level 1 [Member] \| United States Treasury Securities [Member]
Assets [Abstract]
Cash equivalents	7,670	3,848
Investments	228,443	189,444
Level 1 [Member] \| Corporate Bonds [Member]
Assets [Abstract]
Cash equivalents	0	0
Investments	0	0
Level 1 [Member] \| Agency Bonds [Member]
Assets [Abstract]
Investments	0	0
Level 2 [Member]
Assets [Abstract]
Cash equivalents	3,778	12,517
Investments	67,019	69,709
Fair value of financial instruments	70,797	82,226
Liabilities [Abstract]
Total liabilities	0	0
Level 2 [Member] \| Warrant Liability [Member]
Liabilities [Abstract]
Total liabilities	0	0
Level 2 [Member] \| Money Market Mutual Funds [Member]
Assets [Abstract]
Cash equivalents	0	0
Level 2 [Member] \| Commercial Paper [Member]
Assets [Abstract]
Cash equivalents		3,899
Investments	5,147	1,151
Level 2 [Member] \| United States Treasury Securities [Member]
Assets [Abstract]
Cash equivalents	0	0
Investments	0	0
Level 2 [Member] \| Corporate Bonds [Member]
Assets [Abstract]
Cash equivalents	3,778	8,618
Investments	54,159	60,905
Level 2 [Member] \| Agency Bonds [Member]
Assets [Abstract]
Investments	7,713	7,653
Level 3 [Member]
Assets [Abstract]
Cash equivalents	0	0
Investments	0	0
Fair value of financial instruments	0	0
Liabilities [Abstract]
Total liabilities	815	1,512
Level 3 [Member] \| Warrant Liability [Member]
Liabilities [Abstract]
Total liabilities	815	1,512
Level 3 [Member] \| Money Market Mutual Funds [Member]
Assets [Abstract]
Cash equivalents	0	0
Level 3 [Member] \| Commercial Paper [Member]
Assets [Abstract]
Cash equivalents		0
Investments	0	0
Level 3 [Member] \| United States Treasury Securities [Member]
Assets [Abstract]
Cash equivalents	0	0
Investments	0	0
Level 3 [Member] \| Corporate Bonds [Member]
Assets [Abstract]
Cash equivalents	0	0
Investments	0	0
Level 3 [Member] \| Agency Bonds [Member]
Assets [Abstract]
Investments	$ 0	$ 0

Fair Value of Financial Instruments, Changes in Level 3 Liabilities Measured at Fair Value (Details) - Recurring [Member] - Level 3 [Member] - Warrant Liability [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Changes in Fair Value of Warrant Liabilities [Roll Forward]
Fair value, beginning of period	$ 1,512
Fair value adjustments	(697)
Fair value, end of period	$ 815

Fair Value of Financial Instruments, Level 3 Fair Value of the Private Warrants (Details) - Private Warrants [Member]	Mar. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares
Fair Value of the Private Warrants, Assumptions [Abstract]
Term	2 years 25 days	2 years 4 months 20 days
Fair value per warrant (in dollars per share)	$ 1.32	$ 2.45
Stock Price [Member]
Fair Value of the Private Warrants, Assumptions [Abstract]
Measurement input	17.13	18.39
Exercise Price [Member]
Fair Value of the Private Warrants, Assumptions [Abstract]
Measurement input	65.23	65.23
Expected Volatility [Member]
Fair Value of the Private Warrants, Assumptions [Abstract]
Measurement input	0.6738	0.7125
Risk-Free Interest Rate [Member]
Fair Value of the Private Warrants, Assumptions [Abstract]
Measurement input	0.0404	0.0414
Expected Dividend Yield [Member]
Fair Value of the Private Warrants, Assumptions [Abstract]
Measurement input	0	0

Property and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Property and Equipment [Abstract]
Property and equipment, gross	$ 40,817		$ 38,102
Less: accumulated depreciation and amortization	(10,229)		(9,093)
Property and equipment, net	30,588		29,009
Depreciation and amortization	1,135	$ 767	800
Laboratory Equipment [Member]
Property and Equipment [Abstract]
Property and equipment, gross	23,317		21,905
Machinery and Equipment [Member]
Property and Equipment [Abstract]
Property and equipment, gross	11,443		11,326
Computer Equipment [Member]
Property and Equipment [Abstract]
Property and equipment, gross	244		244
Furniture and Fixtures [Member]
Property and Equipment [Abstract]
Property and equipment, gross	2,216		2,135
Leasehold Improvements [Member]
Property and Equipment [Abstract]
Property and equipment, gross	1,694		589
Internal use Software [Member]
Property and Equipment [Abstract]
Property and equipment, gross	$ 1,903		$ 1,903

Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Dec. 01, 2022
Intangible Assets, Net [Abstract]
Gross Carrying Value	$ 25,724
Intangible Assets, Net	25,724	$ 25,724
Goodwill	39,154	$ 39,154
Renovacor, Inc. [Member]
Intangible Assets, Net [Abstract]
Goodwill	8,300		$ 8,339
In Process Research & Development [Member]
Intangible Assets, Net [Abstract]
Gross Carrying Value	25,150
Intangible Assets, Net	25,150
Mice Colony Model [Member]
Intangible Assets, Net [Abstract]
Gross Carrying Value	574
Intangible Assets, Net	$ 574

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accounts Payable and Accrued Expenses [Abstract]
Research and development	$ 17,536	$ 19,100
Employee compensation	4,199	10,006
Property and equipment	1,794	2,095
Professional fees	2,813	1,436
Acquisition related expenses	0	1,153
Government grant payable	597	597
Other	1,670	2,273
Accounts payable and accrued expenses	$ 28,609	$ 36,660

Stockholders' Equity (Details) - USD ($) $ in Thousands, shares in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Feb. 28, 2022
At-the-Market Offering Program [Abstract]
Net proceeds from offering	$ 17,222	$ 0
At-the-Market Offering Program [Member]
At-the-Market Offering Program [Abstract]
Issuance of common stock, net of issuance costs (in shares)	0.9
Gross proceeds, offering amount	$ 17,800
Commissions	600
Net proceeds from offering	$ 17,200
At-the-Market Offering Program [Member] \| Cowen and Company, LLC [Member]
At-the-Market Offering Program [Abstract]
Percentage of cash commission			3.00%
Issuance of common stock, net of issuance costs (in shares)	4.2
Gross proceeds, offering amount	$ 65,800
Commissions	2,000
Net proceeds from offering	$ 63,800

Stock Based Compensation, Share Option Valuation (Details) - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Stock Option Activity [Roll Forward]
Outstanding at beginning of period (in shares)	13,138,870
Granted (in shares)	1,792,097
Exercised (in shares)	(88,429)
Cancelled (in shares)	(191,148)
Outstanding at end of period (in shares)	14,651,390		13,138,870
Options vested and exercisable at end of period (in shares)	10,586,141
Options unvested at ending of period (in shares)	4,065,249
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 14.52
Granted (in dollars per share)	20.36
Exercised (in dollars per share)	12.59
Cancelled (in dollars per share)	33.99
Outstanding at end of period (in dollars per share)	14.99		$ 14.52
Options vested and exercisable at end of period (in dollars per share)	12.6
Options unvested at ending (in dollars per share)	$ 21.24
Weighted-Average Remaining Contractual Term [Abstract]
Outstanding	5 years 10 months 6 days		5 years 5 months 15 days
Granted	6 years 10 months 9 days
Options vested and exercisable	4 years 6 months 7 days
Options unvested	9 years 3 months 25 days
Aggregate Intrinsic Value [Abstract]
Outstanding at beginning of period	$ 118,767
Exercised	631
Outstanding at end of period	97,263		$ 118,767
Options vested and exercisable	92,808
Options unvested	$ 4,455
Weighted average grant date fair value of shares granted (in dollars per share)	$ 13.5	$ 11.6
Total fair value of options vested	$ 11,400	$ 12,500
Employees and Directors [Member]
Weighted-Average Assumptions [Abstract]
Risk-free interest rate	4.02%	1.88%
Expected term	5 years 10 months 17 days	5 years 10 months 9 days
Expected volatility	73.54%	74.07%
Expected dividend yield	0.00%	0.00%
Exercise price (in dollars per share)	$ 20.17	$ 17.85
Fair value of common stock (in dollars per share)	$ 20.17	$ 17.85

Stock Based Compensation, Restricted Stock Units (Details) - Restricted Stock Units (RSU) [Member]

3 Months Ended

Mar. 31, 2023

$ / shares

Number of Shares [Roll Forward]

Beginning balance (in shares)

992,874

Granted (in shares)

764,204

Vested (in shares)

(126,145)

^[1]

Forfeited (in shares)

(8,476)

Ending balance (in shares)

1,622,457

Weighted Average Grant Date Fair Value [Abstract]

Beginning balance (in dollars per share) | $ / shares

$ 16.49

Granted (in dollars per share) | $ / shares

20.23

Vested (in dollars per share) | $ / shares

17.37

^[1]

Forfeited (in dollars per share) | $ / shares

17.19

Ending balance (in dollars per share) | $ / shares

$ 18.18

Common stock shares issued related to tax (in shares)

[1]	Common stock issued is net of 85 shares related to taxes.

Stock Based Compensation, Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock-Based Compensation Expense [Abstract]
Total share based compensation expense	$ 8,915	$ 6,270
Research and Development [Member]
Stock-Based Compensation Expense [Abstract]
Total share based compensation expense	3,819	2,318
General and Administrative [Member]
Stock-Based Compensation Expense [Abstract]
Total share based compensation expense	5,096	3,952
Stock Options [Member]
Stock-Based Compensation Expense [Abstract]
Total share based compensation expense	6,985	5,961
Unrecognized share-based compensation cost	$ 75,400
Weighted average period expected to recognize unrecognized share-based compensation cost	1 year 6 months 7 days
Restricted Stock Units [Member]
Stock-Based Compensation Expense [Abstract]
Total share based compensation expense	$ 1,930	$ 309
Unrecognized share-based compensation cost	$ 75,400
Weighted average period expected to recognize unrecognized share-based compensation cost	1 year 6 months 7 days

Warrants, Rocket Warrants (Details)	3 Months Ended
Warrants, Rocket Warrants (Details)	Mar. 31, 2023 $ / shares shares
Warrants [Member]
Warrants [Abstract]
Outstanding (in shares)	2,595,174
Number of Warrant Shares Outstanding and Exercisable [Abstract]
Beginning balance (in shares)	2,721,267
Granted (in shares)	0
Exercised (in shares)	(126,093)
Ending balance (in shares)	2,595,174
Exercise Price Per Share [Abstract]
Exercised (in dollars per share) \| $ / shares	$ 0.06
24.42 [Member]
Warrants [Abstract]
Exercise price per share (in dollars per share) \| $ / shares	$ 24.42
Outstanding (in shares)	7,051
Grant date	Jun. 28, 2013
Expiration date	Jun. 28, 2023
57.11 [Member]
Warrants [Abstract]
Exercise price per share (in dollars per share) \| $ / shares	$ 57.11
Outstanding (in shares)	603,386
Grant date	Dec. 21, 2020
Expiration date	Dec. 21, 2030
33.63 [Member]
Warrants [Abstract]
Exercise price per share (in dollars per share) \| $ / shares	$ 33.63
Outstanding (in shares)	301,291
Grant date	Aug. 09, 2021
Expiration date	Aug. 09, 2031
22.51 [Member]
Warrants [Abstract]
Exercise price per share (in dollars per share) \| $ / shares	$ 22.51
Outstanding (in shares)	153,155
Grant date	Dec. 17, 2021
Expiration date	Dec. 17, 2031
22.51 [Member]
Warrants [Abstract]
Exercise price per share (in dollars per share) \| $ / shares	$ 22.51
Outstanding (in shares)	153,155
Grant date	Dec. 17, 2021
Expiration date	Dec. 17, 2031
65.23 [Member]
Warrants [Abstract]
Exercise price per share (in dollars per share) \| $ / shares	$ 65.23
Outstanding (in shares)	617,050
Grant date	Dec. 01, 2022
Expiration date	Apr. 23, 2025
65.23 [Member]
Warrants [Abstract]
Exercise price per share (in dollars per share) \| $ / shares	$ 65.23
Outstanding (in shares)	760,086
Grant date	Dec. 01, 2022
Expiration date	Dec. 01, 2026

Warrants, Renovacor Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Warrants [Abstract]
Additional paid-in capital	$ 1,230,319	$ 1,203,074
Public Warrants [Member]
Warrants [Abstract]
Additional paid-in capital	$ 3,400
Public Warrants [Member] \| Common Stock [Member]
Warrants [Abstract]
Warrant to purchase shares of common stock (in shares)	760,086
Warrant to purchase shares of common stock price per share (in dollars per share)	$ 65.23
Private Warrants [Member]
Warrants [Abstract]
Warrant to purchase shares of common stock price per share (in dollars per share)	$ 1.32	$ 2.45
Private Warrants [Member] \| Common Stock [Member]
Warrants [Abstract]
Warrant to purchase shares of common stock (in shares)	617,050
Warrant to purchase shares of common stock price per share (in dollars per share)	$ 65.23
Pre-Funded Warrants [Member] \| Common Stock [Member]
Warrants [Abstract]
Warrant to purchase shares of common stock (in shares)	126,093
Warrant to purchase shares of common stock price per share (in dollars per share)	$ 0.06

Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator [Abstract]
Net loss attributable to common stockholders	$ (58,335)	$ (42,982)
Denominator [Abstract]
Weighted-average common shares outstanding - basic (in shares)	79,453,519	64,509,721
Weighted-average common shares outstanding - diluted (in shares)	79,453,519	64,509,721
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (0.73)	$ (0.67)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (0.73)	$ (0.67)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Warrants exercisable for common shares (in shares)	2,595,174	1,218,038
Restricted stock units convertible for common shares (in shares)	1,622,457	457,709
Options to purchase common shares (in shares)	14,651,390	12,047,299
Weighted average number diluted shares outstanding (in shares)	18,869,021	13,723,046

Commitments and Contingencies, Finance Lease (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) ft² LeaseAgreement	Dec. 31, 2022 USD ($)
Finance Lease [Abstract]
Total lease payments	$ 51,865
Cash security deposit	$ 459	$ 608
NJ Lease Agreement [Member]
Finance Lease [Abstract]
Area of lease \| ft²	103,720
Term of finance lease agreement	15 years
Number of options to renew lease agreement \| LeaseAgreement	2
Term of renewal of finance lease agreement	5 years
Estimated rent payments	$ 1,200
Percentage of annual increase in base rent	3.00%
Total lease payments	$ 29,300
Cash security deposit	$ 300	$ 300
AAV Current Good Manufacturing Practice (cGMP) [Member]
Finance Lease [Abstract]
Area of lease \| ft²	50,000

Commitments and Contingencies, Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Jun. 07, 2018
Operating Leases [Abstract]
Total right-of-use asset	$ 4,369		$ 1,972
Total lease liabilities	3,506		1,088
Rent expense	400	$ 300
Restricted cash	1,340		1,340
Operating and Finance Leases [Member]
Operating Leases [Abstract]
Restricted cash	800		800
Renovacor, Inc. [Member]
Operating Leases [Abstract]
Total right-of-use asset	3,800
Total lease liabilities	$ 3,600
Hopewell, New Jersey and Cambridge [Member]
Operating Leases [Abstract]
Remaining lease term	10 years 3 months
ESB Lease Agreement [Member]
Operating Leases [Abstract]
Term of lease agreement	3 years
Letter of credit				$ 900
Lease expiration date	Aug. 29, 2024
Certificate of deposit	$ 800		$ 800
ESB Lease Agreement Amendment [Member]
Operating Leases [Abstract]
Letter of credit	$ 800
Lease expiration date	Jun. 30, 2024
Inotek Lexington Massachusetts Lease Agreement [Member]
Operating Leases [Abstract]
Lease expiration date	Feb. 28, 2023
Rental income received under sublease agreements	$ 100	$ 100
Remaining lease term	1 year 3 months 18 days
Other Current Assets [Member]
Operating Leases [Abstract]
Security deposit	$ 200

Commitments and Contingencies, Details of Operating and Finance Lease (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Lease cost [Abstract]
Operating lease cost	$ 358
Finance lease cost [Abstract]
Amortization of right of use assets	538
Interest on lease liabilities	468
Total lease cost	1,364
Future Lease Payments of Operating Lease Liabilities [Abstract]
2023 (nine months)	869
2024	798
2025	538
2026	545
2027	506
Thereafter	2,941
Total lease payments	6,197
Less: interest	(1,842)
Total operating lease liabilities	4,355
Future Lease Payments of Finance Lease Liability [Abstract]
2023 (nine months)	1,305
2024	1,791
2025	1,856
2026	1,912
2027	1,969
Thereafter	43,032
Total lease payments	51,865
Less: interest	(30,823)
Total finance lease liability	21,042
Lease assets and liabilities [Abstract]
Operating right-of-use assets	4,369	$ 1,972
Operating current lease liabilities	849	773
Operating noncurrent lease liabilities	3,506	1,088
Total operating lease liabilities	4,355
Finance right-of-use assets	46,133	46,664
Finance current lease liability	1,748	1,736
Finance noncurrent lease liability	19,294	$ 19,269
Total finance lease liability	21,042
Cash paid for amounts included in the measurement of lease liabilities [Abstract]
Operating cash flows from operating leases	261
Cash flows from finance lease	$ 431
Weighted-average remaining lease term - operating leases	8 years 2 months 12 days
Weighted-average remaining lease term - finance lease	21 years 4 months 24 days
Weighted-average discount rate - operating leases	8.08%
Weighted-average discount rate - finance lease	8.96%

Renovacor Acquisition (Details)
$ / shares in Units, $ in Thousands

Dec. 01, 2022

USD ($)

$ / shares

Sep. 19, 2022

Mar. 31, 2023

USD ($)

Dec. 31, 2022

USD ($)

Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]

Goodwill

$ 39,154

Renovacor, Inc. [Member]

Business Combination [Abstract]

Exchange ratio

0.1763

Business Combination, Consideration Transferred [Abstract]

Stock consideration (in shares) | shares

5,291,855

Cash consideration

^[1]

$ 29

Equity consideration, value

2,700

Total consideration

72,265

Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]

Working capital

^[2]

(5,210)

Cash and cash equivalents

42,755

Property and equipment

1,414

Operating lease right-of-use assets

1,161

Other non-current assets

113

IPR&D

25,150

Other intangible asset

574

Operating lease liability

(970)

Deferred tax liability

(1,061)

Net assets acquired

63,926

Goodwill

8,339

$ 8,300

Purchase consideration

$ 72,265

Renovacor, Inc. [Member] | Assumed Warrants [Member]

Business Combination, Consideration Transferred [Abstract]

Stock consideration (in shares) | shares

^[3]

1,503,229

Equity consideration, value

^[3]

$ 7,183

Renovacor, Inc. [Member] | Warrants, Classified as Equity [Member]

Business Combination, Consideration Transferred [Abstract]

Equity consideration, value

5,671

Renovacor, Inc. [Member] | Warrants Classified as Liabilities [Member]

Business Combination, Consideration Transferred [Abstract]

Equity consideration, value

$ 1,512

Renovacor, Inc. [Member] | Stock Options [Member]

Business Combination, Consideration Transferred [Abstract]

Stock consideration (in shares) | shares

367,852

Equity consideration, value

$ 2,163

Renovacor, Inc. [Member] | Time Vesting RSU [Member]

Business Combination, Consideration Transferred [Abstract]

Stock consideration (in shares) | shares

28,798

Equity consideration, value

$ 512

Renovacor, Inc. [Member] | Stock Consideration [Member]

Business Combination, Consideration Transferred [Abstract]

Stock consideration (in shares) | shares

3,391,976

Share price (in dollars per share) | $ / shares

$ 18.39

Equity consideration, value

$ 62,378

[1]	Represents consideration paid for cash in lieu of fractional shares.
[2]	Includes other receivables, prepaid expenses, account payable and accrued liabilities.
[3]	Assumed Renovacor Warrants of $7,183 with $5,671 classified as equity and $1,512 classified as liabilities.

CIRM Grants (Details) - LAD-1 CIRM Grant [Member] $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) Milestone	Apr. 30, 2019 USD ($)
CIRM Grants [Abstract]
Grant award for clinical development support		$ 7.5
Milestone payments received	$ 5.9
Number of milestones achieved \| Milestone	0

Related Party Transactions (Details) - Restricted Stock Units (RSU) [Member] - shares	1 Months Ended	3 Months Ended
	Oct. 31, 2020	Mar. 31, 2023
Related Party Transaction [Abstract]
Shares granted (in shares)		764,204
Spouse of Executive officer [Member]
Related Party Transaction [Abstract]
Shares granted (in shares)	10,000
Vesting period		3 years

401(k) Savings Plan (Details) - USD ($) $ in Millions	3 Months Ended
401(k) Savings Plan (Details) - USD ($) $ in Millions	Mar. 31, 2023	Mar. 31, 2022
401(k) Savings Plan [Abstract]
Percentage of matching employee contributions	4.00%
Matching employee contributions	$ 0.3	$ 0.2